((自动化翻译由路透提供,请见免责声明 ))
路透11月4日 - 远程医疗公司Hims & Hers Health 周一表示,它计划在2025年将诺和诺德(Novo Nordisk) 糖尿病药物利拉鲁肽的仿制药引入其平台。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.